Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Abivax
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
July 2, 2026
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
July 1, 2026
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 1, 2026
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
July 1, 2026
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 1, 2026
Abivax Announces Launch of Public Offering of American Depositary Shares
June 30, 2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
June 29, 2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting
May 29, 2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 28, 2026
Abivax to Present Data on Obefazimod at Digestive Disease Week®
May 26, 2026
1
2
Next Page
→